Literature DB >> 16146557

Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder.

Donald E Tsai1, Nicole A Aqui, John E Tomaszewski, Kim M Olthoff, Vivek N Ahya, Robert M Kotloff, Roy D Bloom, Susan C Brozena, Richard L Hodinka, Edward A Stadtmauer, Stephen J Schuster, Sunita D Nasta, David L Porter, Selina M Luger, Thomas R Klumpp.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is an Epstein-Barr virus (EBV) associated malignancy that occurs in the setting of pharmacologic immunosuppression used after organ transplantation. The presence of monoclonal gammopathy (MG) after organ transplantation is a risk factor for the development of PTLD. We retrospectively explored the characteristics of serum protein electrophoresis (SPEP) in 38 adult solid organ transplant patients with biopsy proven PTLD and SPEP. Twenty-three (61%) had MG with nine (24%) showing multiple MG. Background gammaglobulin levels were abnormal in 13 (34%) patients with five (13%) and eight (21%) having polyclonal hypergammaglobulinemia or hypogammaglobulinemia, respectively. Hypogammaglobulinemia was correlated with the presence of MG (p = 0.01) and polymorphic B-cell hyperplasia histology (p = 0.01). No correlation between SPEP findings and overall survival were noted. With median follow-up of 116 wk (range 2-261 wk), 21 (55%) patients are alive with 20 (53%) in complete remission. Response to reduction in immunosuppression was correlated with improved overall survival (262 wk vs. 68 wk, p = 0.003). Persistence of MG after complete response of the PTLD did not predict relapse. There is a high incidence of MG and gammaglobulin abnormalities in patients with PTLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146557     DOI: 10.1111/j.1399-0012.2005.00388.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

1.  Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder.

Authors:  E A Engels; J Preiksaitis; A Zingone; O Landgren
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

Review 2.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Authors:  Patrizia Chiusolo; Elisabetta Metafuni; Paola Cattani; Nicola Piccirillo; Rosaria Santangelo; Stefania Manzara; Silvia Bellesi; Teresa De Michele; Giuseppe Leone; Simona Sica
Journal:  J Clin Immunol       Date:  2010-08-25       Impact factor: 8.317

4.  Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.

Authors:  Eric A Engels; Barbara Savoldo; Ruth M Pfeiffer; Rene Costello; Adriana Zingone; Helen E Heslop; Ola Landgren
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

5.  Epstein-barr virus related lymphoproliferations after stem cell transplantation.

Authors:  Simona Sica; Elisabetta Metafuni; Silvia Bellesi; Patrizia Chiusolo
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

6.  Plasma cell neoplasms in US solid organ transplant recipients.

Authors:  Eric A Engels; Christina A Clarke; Ruth M Pfeiffer; Charles F Lynch; Dennis D Weisenburger; Todd M Gibson; Ola Landgren; Lindsay M Morton
Journal:  Am J Transplant       Date:  2013-05-01       Impact factor: 9.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.